Packaging and storage
Preserve in tight, light-resistant containers, and store at controlled room temperature.
Labeling
The labeling indicates the Drug Release Test with which the product complies.
Identification
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Drug release 724
Medium:
0.1 N hydrochloric acid; 900 mL.
Apparatus 1 (10-mesh basket):
100 rpm.
Times:
30, 60, and 240 minutes.
Procedure
Dilute filtered portions of the solution under test quantitatively with 0.1 N hydrochloric acid to obtain a test solution having a concentration of cefaclor (C
15H
14ClN
3O
4S) estimated to be about 25 µg per mL. Determine the amount of cefaclor (C
15H
14ClN
3O
4S) dissolved by employing UV absorption at the wavelength of maximum absorbance at about 265 nm, in comparison with a Standard solution having a similar, known concentration of
USP Cefaclor RS in the same
Medium.
Tolerances
The percentages of the labeled amount of cefaclor (C
15H
14ClN
3O
4S) dissolved at the times specified conform to
Acceptance Table 1.
Time (minutes) |
Amount dissolved |
30 |
between 5% and 30% |
60 |
between 20% and 50% |
240 |
not less than 80% |
Dissolution 711
Medium:
0.1 N hydrochloric acid; 900 mL.
Apparatus 1 (10-mesh basket):
100 rpm.
Times:
30, 60, and 240 minutes.
Procedure
Quantitatively dilute filtered portions of the solution under test with 0.1 N hydrochloric acid to obtain a test solution having a concentration of cefaclor (C
15H
14ClN
3O
4S) estimated to be about 25 µg per mL. Determine the amount of cefaclor (C
15H
14ClN
3O
4S) dissolved by employing UV absorption at the wavelength of maximum absorbance at about 265 nm, in comparison with a Standard solution having a similar, known concentration of
USP Cefaclor RS in the same
Medium.
Tolerances
The percentages of the labeled amount of cefaclor (C
15H
14ClN
3O
4S) dissolved at the times specified conform to
Acceptance Table 2.
Time (minutes) |
Amount dissolved |
30 |
between 5% and 30% |
60 |
between 20% and 50% |
240 |
not less than 80% |
(Official April 1, 2006)
Related compounds
Solvent, Blank solution, Solution A, Solution B, Mobile phase, Standard solution, System suitability solution, and Chromatographic system
Proceed as directed for
Related compounds under
Cefaclor.
Test solution
Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the composite, equivalent to about 50 mg of cefaclor, to a 10-mL volumetric flask. Dissolve in Solvent, using brief sonication, if necessary, to achieve dissolution. Avoid heating. Dilute with Solvent to volume, mix, and filter. Use this Test solution within 3 hours if stored at room temperature, or within 20 hours when stored under refrigeration.
Procedure
Separately inject equal volumes (about 20 µL) of the
Standard solution and the
Test solution into the chromatograph, record the chromatograms, and measure the peak area responses for all the peaks. Calculate the mg of each related compound in the portion of Tablets taken by the formula:
0.01CP(ri / rS),
in which the terms are as defined for
Related compounds under
Cefaclor. Not more than 0.6% of any individual cefaclor-related compound is found; and the sum of all cefaclor-related compounds found is not more than 2.0%, not including the contribution of any peak that gives a result of less than 0.1%.
Assay
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system
Proceed as directed in the
Assay under
Cefaclor.
Assay preparation
Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 75 mg of cefaclor, to a 250-mL volumetric flask, dilute with Mobile phase to volume, and mix. Sonicate, if necessary, to dissolve the cefaclor. Filter to obtain a clear solution.
Procedure
Proceed as directed in the
Assay under
Cefaclor. Calculate the quantity, in mg, of cefaclor (C
15H
14ClN
3O
4S) in the portion of Tablets taken by the formula:
5WS (P/1000)(rU / rS),
in which the terms are as defined therein.
Auxiliary Information
Staff Liaison :
Brian D. Gilbert, Ph.D., Scientist
Expert Committee : (MDANT05) Monograph Development-Antibiotics
USP29NF24 Page 402
Pharmacopeial Forum : Volume No. 31(1) Page 42
Phone Number : 1-301-816-8223